TY  - CONF
AU  - Ljubičić, Jelena
AU  - Bogdanović, Aleksandar
AU  - Babić, Tamara
AU  - Despotović, Jovana
AU  - Dugalić, Vladimir
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2100
AB  - Background: Our previous study has identified variant rs745430558 in the SMAD4 gene promoter as potential biomarker for adenocarcinoma of the pancreas. The allele delTT (10T instead of 12T) was present in malignant pancreatic tissue with a prevalence of 88%. As analysis of cfDNA in liquid biopsy represents a noninvasive approach for the diagnosis and monitoring of malignancies, the aim of this study was to determine the presence of 12T and 10T alleles in the peripheral blood of patients with suspected pancreatic malignancy. Material and Methods: The study was performed using cell-free DNA (cfDNA) isolated from the serum of 15 patients with morphological alterations of the pancreas. The presence of 12T and 10T alleles was assessed by allele specific quantitative real-time PCR. Results: Of 15 analyzed samples, 13 were diagnosed with adenocarcinoma of the pancreas (AcP), 1 with neuroendocrine tumor (NET), and 1 with pancreatitis. The 10T allele was present in 84.7% of cases with AcP and also in the sample from the patient with NET. In patient with pancreatitis only the 12T allele was detected. Conclusion: Our research has shown that the results of liquid biopsy of patients with AcP are in agreement with tissue specimens analysis. Targeted detection of the rs745430558 10T variant in patients with suspected pancreatic malignancies could be a potential biomarker for diagnosis of AcP in the future.
PB  - Belgrade :  Serbian Association on for Cancer Research
C3  - 6th Congress of the Serbian Association for Cancer Research (SDIR)
T1  - Variant rs745430558 in the SMAD4 gene promoter as a biomarker for adenocarcinoma of the pancreas
EP  - 85
IS  - 1
SP  - 85
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2100
ER  - 

@conference{
author = "Ljubičić, Jelena and Bogdanović, Aleksandar and Babić, Tamara and Despotović, Jovana and Dugalić, Vladimir and Nikolić, Aleksandra",
year = "2023",
abstract = "Background: Our previous study has identified variant rs745430558 in the SMAD4 gene promoter as potential biomarker for adenocarcinoma of the pancreas. The allele delTT (10T instead of 12T) was present in malignant pancreatic tissue with a prevalence of 88%. As analysis of cfDNA in liquid biopsy represents a noninvasive approach for the diagnosis and monitoring of malignancies, the aim of this study was to determine the presence of 12T and 10T alleles in the peripheral blood of patients with suspected pancreatic malignancy. Material and Methods: The study was performed using cell-free DNA (cfDNA) isolated from the serum of 15 patients with morphological alterations of the pancreas. The presence of 12T and 10T alleles was assessed by allele specific quantitative real-time PCR. Results: Of 15 analyzed samples, 13 were diagnosed with adenocarcinoma of the pancreas (AcP), 1 with neuroendocrine tumor (NET), and 1 with pancreatitis. The 10T allele was present in 84.7% of cases with AcP and also in the sample from the patient with NET. In patient with pancreatitis only the 12T allele was detected. Conclusion: Our research has shown that the results of liquid biopsy of patients with AcP are in agreement with tissue specimens analysis. Targeted detection of the rs745430558 10T variant in patients with suspected pancreatic malignancies could be a potential biomarker for diagnosis of AcP in the future.",
publisher = "Belgrade :  Serbian Association on for Cancer Research",
journal = "6th Congress of the Serbian Association for Cancer Research (SDIR)",
title = "Variant rs745430558 in the SMAD4 gene promoter as a biomarker for adenocarcinoma of the pancreas",
pages = "85-85",
number = "1",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2100"
}

Ljubičić, J., Bogdanović, A., Babić, T., Despotović, J., Dugalić, V.,& Nikolić, A.. (2023). Variant rs745430558 in the SMAD4 gene promoter as a biomarker for adenocarcinoma of the pancreas. in 6th Congress of the Serbian Association for Cancer Research (SDIR)
Belgrade :  Serbian Association on for Cancer Research.(1), 85-85.
https://hdl.handle.net/21.15107/rcub_imagine_2100

Ljubičić J, Bogdanović A, Babić T, Despotović J, Dugalić V, Nikolić A. Variant rs745430558 in the SMAD4 gene promoter as a biomarker for adenocarcinoma of the pancreas. in 6th Congress of the Serbian Association for Cancer Research (SDIR). 2023;(1):85-85.
https://hdl.handle.net/21.15107/rcub_imagine_2100 .

Ljubičić, Jelena, Bogdanović, Aleksandar, Babić, Tamara, Despotović, Jovana, Dugalić, Vladimir, Nikolić, Aleksandra, "Variant rs745430558 in the SMAD4 gene promoter as a biomarker for adenocarcinoma of the pancreas" in 6th Congress of the Serbian Association for Cancer Research (SDIR), no. 1 (2023):85-85,
https://hdl.handle.net/21.15107/rcub_imagine_2100 .

TY  - JOUR
AU  - Rosić, Jovana
AU  - Miladinov, Marko
AU  - Dragičević, Sandra
AU  - Erić, Katarina
AU  - Bogdanović, Aleksandar
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1769
AB  - Considering the impact of SMAD7 deregulation in colorectal cancer (CRC) progression and the
significance of single nucleotide variant (SNV)-mediated disruptions of microRNA (miRNA)-dependent regulation
for cancer susceptibility, our study aimed to analyze genetic variation in the SMAD7 3′ untranslated region (
3′UTR) in CRC, measure differences in allelic mRNA expression, and evaluate its interference with miRNAmediated
post-transcriptional regulation.
Patients and Methods: This study included 80 patients with different CRC stages and six human colon cancer cell
lines of various histological origins. SMAD7 3′ UTR was analyzed by direct sequencing, followed by the relative
quantification of differential allelic expression of detected variants by allele-specific qRT-PCR. In silico tools were
employed for predictions of regulatory consequences of detected variants.
Results: A total of four different SNVs in one cell line and nine patients were found, among which were a novel
somatic point variant and three already known germline variants (rs16950113, rs1050799536, and
rs1043778717). All evaluated SNVs exhibited variable extents of allelic imbalance in expression. In silico analysis
predicted significant effects of SNVs on miRNA binding efficiency, with each SNV disrupting existing and
creating new target sites for one or more miRNAs.
Conclusion: Imbalance observed in the expression of SNV alleles altering miRNA binding suggests that all
investigated SNVs are potential contributing factors impacting SMAD7 expression regulation in CRC that further
studies should investigate.
PB  - Elsevier
T2  - Gene
T1  - Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance
SP  - 147217
VL  - 859
DO  - doi.org/10.1016/j.gene.2023.147217
ER  - 

@article{
author = "Rosić, Jovana and Miladinov, Marko and Dragičević, Sandra and Erić, Katarina and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2023",
abstract = "Considering the impact of SMAD7 deregulation in colorectal cancer (CRC) progression and the
significance of single nucleotide variant (SNV)-mediated disruptions of microRNA (miRNA)-dependent regulation
for cancer susceptibility, our study aimed to analyze genetic variation in the SMAD7 3′ untranslated region (
3′UTR) in CRC, measure differences in allelic mRNA expression, and evaluate its interference with miRNAmediated
post-transcriptional regulation.
Patients and Methods: This study included 80 patients with different CRC stages and six human colon cancer cell
lines of various histological origins. SMAD7 3′ UTR was analyzed by direct sequencing, followed by the relative
quantification of differential allelic expression of detected variants by allele-specific qRT-PCR. In silico tools were
employed for predictions of regulatory consequences of detected variants.
Results: A total of four different SNVs in one cell line and nine patients were found, among which were a novel
somatic point variant and three already known germline variants (rs16950113, rs1050799536, and
rs1043778717). All evaluated SNVs exhibited variable extents of allelic imbalance in expression. In silico analysis
predicted significant effects of SNVs on miRNA binding efficiency, with each SNV disrupting existing and
creating new target sites for one or more miRNAs.
Conclusion: Imbalance observed in the expression of SNV alleles altering miRNA binding suggests that all
investigated SNVs are potential contributing factors impacting SMAD7 expression regulation in CRC that further
studies should investigate.",
publisher = "Elsevier",
journal = "Gene",
title = "Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance",
pages = "147217",
volume = "859",
doi = "doi.org/10.1016/j.gene.2023.147217"
}

Rosić, J., Miladinov, M., Dragičević, S., Erić, K., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2023). Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance. in Gene
Elsevier., 859, 147217.
https://doi.org/doi.org/10.1016/j.gene.2023.147217

Rosić J, Miladinov M, Dragičević S, Erić K, Bogdanović A, Krivokapić Z, Nikolić A. Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance. in Gene. 2023;859:147217.
doi:doi.org/10.1016/j.gene.2023.147217 .

Rosić, Jovana, Miladinov, Marko, Dragičević, Sandra, Erić, Katarina, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "Genetic analysis and allele-specific expression of SMAD7 3′UTR variants in human colorectal cancer reveal a novel somatic variant exhibiting allelic imbalance" in Gene, 859 (2023):147217,
https://doi.org/doi.org/10.1016/j.gene.2023.147217 . .

TY  - JOUR
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Dragičević, Sandra
AU  - Galun, Danijel
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1588
AB  - This study aimed to examine the expression pattern of tumoral and circulating miR-93-5p in patients with colorectal cancer (CRC) liver metastasis (CRLM) and to explore its predictive and prognostic potential. CRLM tissue, surrounding non-tumor liver tissue, and serum were obtained from 35 patients with CRLM. The expression pattern of tissue and circulating miR-93-5p in patients with CRLM was determined using quantitative polymerase chain reaction, using miR-16-5p for normalization. Sample-based cut-off values for CRLM and serum miR-93-5p expression were calculated using Receiver Operating Characteristic curve analysis to stratify the patients into high and low miR-93-5p expression groups which were that compared with patients??? clinicopathological data, therapy response, one-year disease-free survival, and disease recurrence. Relative miR-93-5p expression was higher in CRLM in comparison to the non-metastatic liver tissue (p lt 0.001). CRLM miR-93-5p expression showed moderate negative correlation with carcinoembryonic antigen levels (r=???0.406; p=0.016). There were no differences in high-/low-miR-93-5p expression and therapy responders vs. non-responders, which was confirmed in vitro using metastatic and normal colonic cells SW620 and HCEC-1CT, respectively. No difference was observed in one-year recurrence-free survival in patients with high vs. low miR-93-5p expression in CRLM or serum. However, high miR-93-5p serum levels were significantly associated with early disease recurrence (p=0.035). In conclusion, miR-93-5p serum levels could be potentially used as a prognostic factor for early disease recurrence in CRLM patients.
PB  - Aepress Sro, Bratislava
T2  - Neoplasma
T1  - Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases
EP  - 442
IS  - 2
SP  - 430
VL  - 69
DO  - 10.4149/neo_2021_210603N749
ER  - 

@article{
author = "Despotović, Jovana and Bogdanović, Aleksandar and Dragičević, Sandra and Galun, Danijel and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2022",
abstract = "This study aimed to examine the expression pattern of tumoral and circulating miR-93-5p in patients with colorectal cancer (CRC) liver metastasis (CRLM) and to explore its predictive and prognostic potential. CRLM tissue, surrounding non-tumor liver tissue, and serum were obtained from 35 patients with CRLM. The expression pattern of tissue and circulating miR-93-5p in patients with CRLM was determined using quantitative polymerase chain reaction, using miR-16-5p for normalization. Sample-based cut-off values for CRLM and serum miR-93-5p expression were calculated using Receiver Operating Characteristic curve analysis to stratify the patients into high and low miR-93-5p expression groups which were that compared with patients??? clinicopathological data, therapy response, one-year disease-free survival, and disease recurrence. Relative miR-93-5p expression was higher in CRLM in comparison to the non-metastatic liver tissue (p lt 0.001). CRLM miR-93-5p expression showed moderate negative correlation with carcinoembryonic antigen levels (r=???0.406; p=0.016). There were no differences in high-/low-miR-93-5p expression and therapy responders vs. non-responders, which was confirmed in vitro using metastatic and normal colonic cells SW620 and HCEC-1CT, respectively. No difference was observed in one-year recurrence-free survival in patients with high vs. low miR-93-5p expression in CRLM or serum. However, high miR-93-5p serum levels were significantly associated with early disease recurrence (p=0.035). In conclusion, miR-93-5p serum levels could be potentially used as a prognostic factor for early disease recurrence in CRLM patients.",
publisher = "Aepress Sro, Bratislava",
journal = "Neoplasma",
title = "Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases",
pages = "442-430",
number = "2",
volume = "69",
doi = "10.4149/neo_2021_210603N749"
}

Despotović, J., Bogdanović, A., Dragičević, S., Galun, D., Krivokapić, Z.,& Nikolić, A.. (2022). Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases. in Neoplasma
Aepress Sro, Bratislava., 69(2), 430-442.
https://doi.org/10.4149/neo_2021_210603N749

Despotović J, Bogdanović A, Dragičević S, Galun D, Krivokapić Z, Nikolić A. Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases. in Neoplasma. 2022;69(2):430-442.
doi:10.4149/neo_2021_210603N749 .

Despotović, Jovana, Bogdanović, Aleksandar, Dragičević, Sandra, Galun, Danijel, Krivokapić, Zoran, Nikolić, Aleksandra, "Prognostic potential of circulating miR-93-5p in patients with colorectal cancer liver metastases" in Neoplasma, 69, no. 2 (2022):430-442,
https://doi.org/10.4149/neo_2021_210603N749 . .

TY  - JOUR
AU  - Bogdanović, Aleksandar
AU  - Despotović, Jovana
AU  - Galun, Danijel
AU  - Bidzić, Nemanja
AU  - Nikolić, Aleksandra
AU  - Rosić, Jovana
AU  - Krivokapić, Zoran
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1490
AB  - Purpose: There are limited data on expression of epithelial-mesenchymal transition (EMT) markers in patients with colorectal liver metastases (CRLM). The study aim was to evaluate the expression and prognostic significance of E-cadherin (CDH1), fibronectin (FN1) and vimentin (VIM) in patients with CRLM after curative-intent liver resection. Patients and Methods: Thirty patients with CRLM managed by curative-intent liver resection were included in this prospective pilot study. Blood samples, colorectal liver metastases and surrounding non-tumor liver tissue were collected. Expression of CDH1, FN1 and VIM was analyzed by quantitative real-time polymerase chain reaction. Expression in CRLM and non-tumor liver tissue was compared, while expression in serum was correlated with CRLM expression. One-year recurrence-free survival was compared between patients with low and high CDH1, FN1 and VIM expression. Results: The expression of CDH1 was similar in CRLM and non-tumor liver tissues, while FN1 and VIM expression was significantly lower in metastatic tissue (P=0.003 and pP lt  0.001, respectively). Serum expression of CDH1 and VIM was detected in 66.7% and 93.3% of patients, respectively, while FN1 was not detected in any of the patients. The correlation of CDH1 and VIM expression between CRLM and serum was not statistically significant. Decreased CDH1 expression in CRLM and decreased VIM expression in serum were associated with early recurrence after surgical treatment of CRLM. Conclusion: Lower expression of CDH1 in CRLM and lower serum expression of VIM were found to be associated with early recurrence after liver resection for CRLM.
PB  - Dove Medical Press Ltd, Albany
T2  - Cancer Management and Research
T1  - Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection
EP  - 171
SP  - 163
VL  - 13
DO  - 10.2147/CMAR.S287974
ER  - 

@article{
author = "Bogdanović, Aleksandar and Despotović, Jovana and Galun, Danijel and Bidzić, Nemanja and Nikolić, Aleksandra and Rosić, Jovana and Krivokapić, Zoran",
year = "2021",
abstract = "Purpose: There are limited data on expression of epithelial-mesenchymal transition (EMT) markers in patients with colorectal liver metastases (CRLM). The study aim was to evaluate the expression and prognostic significance of E-cadherin (CDH1), fibronectin (FN1) and vimentin (VIM) in patients with CRLM after curative-intent liver resection. Patients and Methods: Thirty patients with CRLM managed by curative-intent liver resection were included in this prospective pilot study. Blood samples, colorectal liver metastases and surrounding non-tumor liver tissue were collected. Expression of CDH1, FN1 and VIM was analyzed by quantitative real-time polymerase chain reaction. Expression in CRLM and non-tumor liver tissue was compared, while expression in serum was correlated with CRLM expression. One-year recurrence-free survival was compared between patients with low and high CDH1, FN1 and VIM expression. Results: The expression of CDH1 was similar in CRLM and non-tumor liver tissues, while FN1 and VIM expression was significantly lower in metastatic tissue (P=0.003 and pP lt  0.001, respectively). Serum expression of CDH1 and VIM was detected in 66.7% and 93.3% of patients, respectively, while FN1 was not detected in any of the patients. The correlation of CDH1 and VIM expression between CRLM and serum was not statistically significant. Decreased CDH1 expression in CRLM and decreased VIM expression in serum were associated with early recurrence after surgical treatment of CRLM. Conclusion: Lower expression of CDH1 in CRLM and lower serum expression of VIM were found to be associated with early recurrence after liver resection for CRLM.",
publisher = "Dove Medical Press Ltd, Albany",
journal = "Cancer Management and Research",
title = "Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection",
pages = "171-163",
volume = "13",
doi = "10.2147/CMAR.S287974"
}

Bogdanović, A., Despotović, J., Galun, D., Bidzić, N., Nikolić, A., Rosić, J.,& Krivokapić, Z.. (2021). Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection. in Cancer Management and Research
Dove Medical Press Ltd, Albany., 13, 163-171.
https://doi.org/10.2147/CMAR.S287974

Bogdanović A, Despotović J, Galun D, Bidzić N, Nikolić A, Rosić J, Krivokapić Z. Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection. in Cancer Management and Research. 2021;13:163-171.
doi:10.2147/CMAR.S287974 .

Bogdanović, Aleksandar, Despotović, Jovana, Galun, Danijel, Bidzić, Nemanja, Nikolić, Aleksandra, Rosić, Jovana, Krivokapić, Zoran, "Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection" in Cancer Management and Research, 13 (2021):163-171,
https://doi.org/10.2147/CMAR.S287974 . .

TY  - CONF
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Dragičević, Sandra
AU  - Galun, Danijel
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1802
UR  - https://www.eacr2021.org/

https://fightcolorectalcancer.org/blog/recap-rally-on-research-eao-crc/
AB  - Approximately half of colorectal cancer (CRC) patients will develop liver metastases
(CRLM) during the course of the disease. Even with the use of modern adjuvant systemic treatment,
almost two thirds of metastatic colorectal cancer (mCRC) patients will eventually develop recurrent
disease after curative-intent surgery, thus the new prognostic biomarkers are necessary. The expression
signatures of microRNAs (miRNAs), a class of non-coding RNAs, have been associated with the
diagnosis, prognosis, and therapeutic response in CRC. The expression pattern and prognostic potential of
miR-93-5p has been studied previously in CRC but not in mCRC. The aim of this study was to examine
the expression pattern and prognostic potential of tumoral and circulating miR-93-5p in patients with
CRLM.
PB  - EACR 2021 Virtual Congress: Innovative Cancer Science
C3  - European Association for Cancer Research
T1  - Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1802
ER  - 

@conference{
author = "Despotović, Jovana and Bogdanović, Aleksandar and Dragičević, Sandra and Galun, Danijel and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2021",
abstract = "Approximately half of colorectal cancer (CRC) patients will develop liver metastases
(CRLM) during the course of the disease. Even with the use of modern adjuvant systemic treatment,
almost two thirds of metastatic colorectal cancer (mCRC) patients will eventually develop recurrent
disease after curative-intent surgery, thus the new prognostic biomarkers are necessary. The expression
signatures of microRNAs (miRNAs), a class of non-coding RNAs, have been associated with the
diagnosis, prognosis, and therapeutic response in CRC. The expression pattern and prognostic potential of
miR-93-5p has been studied previously in CRC but not in mCRC. The aim of this study was to examine
the expression pattern and prognostic potential of tumoral and circulating miR-93-5p in patients with
CRLM.",
publisher = "EACR 2021 Virtual Congress: Innovative Cancer Science",
journal = "European Association for Cancer Research",
title = "Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1802"
}

Despotović, J., Bogdanović, A., Dragičević, S., Galun, D., Krivokapić, Z.,& Nikolić, A.. (2021). Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases. in European Association for Cancer Research
EACR 2021 Virtual Congress: Innovative Cancer Science..
https://hdl.handle.net/21.15107/rcub_imagine_1802

Despotović J, Bogdanović A, Dragičević S, Galun D, Krivokapić Z, Nikolić A. Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases. in European Association for Cancer Research. 2021;.
https://hdl.handle.net/21.15107/rcub_imagine_1802 .

Despotović, Jovana, Bogdanović, Aleksandar, Dragičević, Sandra, Galun, Danijel, Krivokapić, Zoran, Nikolić, Aleksandra, "Prognostic potential of circulating miR-93-5p in patients with colorectal liver metastases" in European Association for Cancer Research (2021),
https://hdl.handle.net/21.15107/rcub_imagine_1802 .

TY  - JOUR
AU  - Rosić, Jovana
AU  - Dragičević, Sandra
AU  - Miladinov, Marko
AU  - Despotović, Jovana
AU  - Bogdanović, Aleksandar
AU  - Krivokapić, Zoran
AU  - Nikolić, Aleksandra
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1469
AB  - Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Experimental and Molecular Pathology
T1  - SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response
VL  - 123
DO  - 10.1016/j.yexmp.2021.104714
ER  - 

@article{
author = "Rosić, Jovana and Dragičević, Sandra and Miladinov, Marko and Despotović, Jovana and Bogdanović, Aleksandar and Krivokapić, Zoran and Nikolić, Aleksandra",
year = "2021",
abstract = "Inhibitory SMAD7 and common mediator SMAD4 play crucial roles in SMAD-dependent TGF-I3 signaling that is often disrupted in colorectal cancer (CRC). This study aimed to profile the expression of SMAD7 and SMAD4 in primary and metastatic CRC and to evaluate their significance in disease progression and therapy response. The expression of SMAD7 and SMAD4 genes was analyzed by quantitative real-time PCR in tissues from 35 primary and metastatic CRC patients and in vitro in 7 human cell lines originating from colon tissue. Expression levels of SMAD7 and SMAD4, as well as their ratio, were determined and their association with tumor characteristics and response to therapy were evaluated. SMAD4 level was significantly lower in tumors compared to non-tumor tissues in both primary (p = 0.001) and metastatic (p = 0.001) CRC patients, while tumor expression of SMAD7 was significantly lower from non-tumor tissue only in metastatic patients (p = 0.017). SMAD7/SMAD4 ratio was elevated in CRC primary tumor tissues and cell lines compared to corresponding non-tumor tissues and cell line, respectively (p = 0.003). SMAD7 expression was significantly elevated in primary tumor tissues obtained from responders to neoadjuvant chemoradiotherapy (nCRT) compared to non-responders (p = 0.014). Alterations of expression and ratio of SMAD7 and SMAD4 in CRC cell lines, primary rectal cancer, and liver metastasis emphasize the importance of these genes in different stages of disease progression. Differential expression of SMAD7 in responders versus non-responders to nCRT should be further investigated for its potential predictive value.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Experimental and Molecular Pathology",
title = "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response",
volume = "123",
doi = "10.1016/j.yexmp.2021.104714"
}

Rosić, J., Dragičević, S., Miladinov, M., Despotović, J., Bogdanović, A., Krivokapić, Z.,& Nikolić, A.. (2021). SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology
Academic Press Inc Elsevier Science, San Diego., 123.
https://doi.org/10.1016/j.yexmp.2021.104714

Rosić J, Dragičević S, Miladinov M, Despotović J, Bogdanović A, Krivokapić Z, Nikolić A. SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response. in Experimental and Molecular Pathology. 2021;123.
doi:10.1016/j.yexmp.2021.104714 .

Rosić, Jovana, Dragičević, Sandra, Miladinov, Marko, Despotović, Jovana, Bogdanović, Aleksandar, Krivokapić, Zoran, Nikolić, Aleksandra, "SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response" in Experimental and Molecular Pathology, 123 (2021),
https://doi.org/10.1016/j.yexmp.2021.104714 . .